AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ceftolozane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, cefalosporanic acid derivatives | 4922 | 689293-68-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Ceftolozane belongs to the cephalosporin class of antibacterial drugs. The bactericidal action of ceftolozane results from inhibition of cell wall biosynthesis, and is mediated through binding to penicillin-binding proteins (PBPs). Ceftolozane is an inhibitor of PBPs of P. aeruginosa (e.g., PBP1b, PBP1c, and PBP3) and E. coli (e.g., PBP3).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| Vd (Volume of distribution) | 0.17 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.81 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.58 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 19, 2014 | FDA | CUBIST PHARMS | |
| Jan. 8, 2019 | PMDA | MSD K.K. | |
| Sept. 18, 2015 | EMA | MERCK SHARP & DOHME B.V. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DI54 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Other cephalosporins and penems |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000892 | Anti-Infective Agents, Urinary |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D065093 | beta-Lactamase Inhibitors |
| FDA CS | M0003827 | Cephalosporins |
| FDA EPC | N0000175488 | Cephalosporin Antibacterial |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
Related Drugs by ATC class:
J01DI Other cephalosporins and penems 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Abscess of liver | indication | 27916005 | |
| Acute pyelonephritis | indication | 36689008 | DOID:559 |
| Urinary tract infectious disease | indication | 68566005 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Abdominal abscess | indication | 75100008 | |
| Cholecystitis | indication | 76581006 | DOID:1949 |
| Infectious disease of abdomen | indication | 128070006 | |
| Bacterial peritonitis | indication | 197171003 | |
| Bacterial cystitis | indication | 424551004 | |
| Nosocomial pneumonia | indication | 425464007 | |
| Ventilator-acquired pneumonia | indication | 429271009 | |
| Sepsis caused by Haemophilus influenzae | indication | 447685007 | |
| Sepsis caused by Serratia | indication | 449084002 | |
| Bacterial pyelonephritis | indication | 838353009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.97 | acidic |
| pKa2 | 3.5 | acidic |
| pKa3 | 11.54 | acidic |
| pKa4 | 12.82 | acidic |
| pKa5 | 13.65 | acidic |
| pKa6 | 9.85 | Basic |
| pKa7 | 4.05 | Basic |
| pKa8 | 0.73 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | METHODS FOR TREATING BACTERIAL INFECTIONS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | METHODS OF TREATING BACTERIAL ILLNESSES |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | TREATMENT, IN COMBINATION WITH METRONIDAZOLE, OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED INTRA ABDOMINAL INFECTIONS (CIAI) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10028963 | Sept. 7, 2032 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10028963 | Sept. 7, 2032 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10028963 | Sept. 7, 2032 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10028963 | Sept. 7, 2032 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 9724353 | Sept. 7, 2032 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 9724353 | Sept. 7, 2032 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 9724353 | Sept. 7, 2032 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 9724353 | Sept. 7, 2032 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | TREATMENT IN COMBINATION WITH METRONIDAZOLE, OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED INTRA ABDOMINAL INFECTIONS (CIAI) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 11278622 | March 14, 2034 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 11278622 | March 14, 2034 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 11278622 | March 14, 2034 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 11278622 | March 14, 2034 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | TREATMENT, IN COMBINATION WITH METRONIDAZOLE, OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED INTRA ABDOMINAL INFECTIONS (CIAI) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10376496 | Sept. 9, 2034 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10376496 | Sept. 9, 2034 | TREATMENT OF COMPLICATED INTRA ABDOMINAL INFECTIONS (CIAI), IN ADULT AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS, IN COMBINATION WITH METRONIDAZOLE |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10376496 | Sept. 9, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10376496 | Sept. 9, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS IN ADULT AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10933053 | Sept. 9, 2034 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN ADULT AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10933053 | Sept. 9, 2034 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10933053 | Sept. 9, 2034 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN ADULT AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10933053 | Sept. 9, 2034 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | May 12, 2029 | NEW PATIENT POPULATION |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | Nov. 12, 2029 | PEDIATRIC EXCLUSIVITY |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 37A4IES95Q | UNII |
| D10097 | KEGG_DRUG |
| 4034036 | VUID |
| N0000191292 | NUI |
| 936111-69-2 | SECONDARY_CAS_RN |
| 4034035 | VANDF |
| 4034036 | VANDF |
| C3852726 | UMLSCUI |
| CHEBI:134719 | CHEBI |
| CHEMBL2103872 | ChEMBL_ID |
| 53234134 | PUBCHEM_CID |
| DB09050 | DRUGBANK_ID |
| CHEMBL1213250 | ChEMBL_ID |
| 9426 | INN_ID |
| C519491 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10788 | IUPHAR_LIGAND_ID |
| C000594038 | MESH_SUPPLEMENTAL_RECORD_UI |
| 1597608 | RXNORM |
| 231579 | MMSL |
| 30783 | MMSL |
| d08325 | MMSL |
| 015822 | NDDF |
| 015823 | NDDF |
| 708792003 | SNOMEDCT_US |
| 734470005 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ZERBAXA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 67919-030 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 28 sections |
| ZERBAXA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 67919-030 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 28 sections |